This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Anticancer agents | |
|---|---|
| Name | Anticancer agents |
| Specialty | Oncology |
Anticancer agents are substances used to treat cancer by inhibiting malignant cell growth, inducing apoptosis, or modulating the host immune response. These agents encompass a wide range of classes, including small molecules, biologics, and cell-based therapies developed and applied across specialties such as medical oncology, surgical oncology, and radiation oncology. Their discovery, regulatory approval, and clinical deployment involve institutions like the Food and Drug Administration, multinational pharmaceutical companies, and academic centers such as Johns Hopkins Hospital and Mayo Clinic.
Anticancer agents originate from natural sources like species studied by Alexander Fleming and compounds isolated in programs at National Cancer Institute and private firms such as Roche and Pfizer, or from targeted design at institutions including Massachusetts Institute of Technology and University of Cambridge. Historical milestones in the field involve events and figures such as the development of alkylating agents linked to observations from the Battle of Ypres and pioneering chemotherapy trials at Memorial Sloan Kettering Cancer Center guided by clinicians affiliated with Harvard Medical School and Stanford University School of Medicine. The landscape of therapeutic approvals has been shaped by legislation and agencies including the European Medicines Agency and policy debates in forums like the United States Congress.
Agents are classified into categories represented in landmark texts and curricula at institutions like University of Oxford and Columbia University: cytotoxic chemotherapeutics (e.g., alkylating agents, antimetabolites), targeted therapies (e.g., tyrosine kinase inhibitors), biologics (e.g., monoclonal antibodies), immunotherapies (e.g., checkpoint inhibitors), and cellular therapies (e.g., CAR T cells). Representative mechanisms reference molecules and discoveries associated with laboratories at Cold Spring Harbor Laboratory and researchers such as James Allison and Tasuku Honjo who elucidated immune checkpoints targeted by agents used in clinics like Cleveland Clinic and trials coordinated by networks such as National Institutes of Health. Examples tied to corporate development include kinase inhibitors from Novartis and monoclonal antibodies developed by Genentech.
Preclinical screening at centers like Broad Institute and toxicology studies funded by programs at National Institute of Allergy and Infectious Diseases precede phased clinical trials run by cooperative groups such as Eastern Cooperative Oncology Group and sponsored by companies including AstraZeneca. Demonstration of safety and efficacy in Phase I–III trials often leads to submission dossiers to regulators like the Food and Drug Administration and European Medicines Agency, with accelerated pathways influenced by precedents such as approvals reviewed following advisory committee meetings at Advisory Committee on Immunization Practices-style panels. Intellectual property protection involves entities like United States Patent and Trademark Office and litigation in courts such as the United States Court of Appeals for the Federal Circuit.
Clinical application integrates systemic pharmacotherapy with modalities practiced at centers like Dana-Farber Cancer Institute and MD Anderson Cancer Center including combination regimens, perioperative chemotherapy coordinated with American Society of Clinical Oncology guidelines, and adjuvant or neoadjuvant strategies informed by trials from groups such as European Organisation for Research and Treatment of Cancer. Delivery routes, dosing schedules, and supportive care involve collaborations with departments at University of California, San Francisco and pharmacy programs at University of Pennsylvania. Specialized applications include hematologic malignancy protocols developed at Fred Hutchinson Cancer Research Center and solid tumor regimens instituted in multicenter trials by organizations like SWOG.
Toxicity profiles for agents are cataloged in compendia used by clinicians at Johns Hopkins Hospital and pharmacists trained at University College London, with common adverse effects such as myelosuppression, mucositis, cardiotoxicity, and neuropathy. Management strategies draw on research from institutions including Memorial Sloan Kettering Cancer Center and guidelines from bodies like American Society of Hematology and National Comprehensive Cancer Network. Interventions may involve growth factor support exemplified by products developed by Amgen, antiemetic regimens reflecting trials conducted at Mayo Clinic, and cardiology-oncology collaborations modeled on programs at Cleveland Clinic.
Mechanisms of resistance—such as efflux pump upregulation described in studies from University of Tokyo and secondary mutations characterized by teams at Cold Spring Harbor Laboratory—drive rational combination strategies. Combinations informed by translational research at Dana-Farber Cancer Institute and consortiums like Cancer Research UK pair cytotoxics with targeted agents or immunotherapies, mirroring successful regimens developed at Memorial Sloan Kettering Cancer Center and tested in cooperative trials by Children's Oncology Group. Adaptive trial designs promoted by groups including Clinical Trials Transformation Initiative facilitate evaluation of resistance-overcoming approaches.
Emerging directions span gene-editing approaches from labs at Broad Institute and Stanford University School of Medicine, personalized neoantigen vaccines researched at Salk Institute for Biological Studies and Palo Alto Veterans Institute for Research, and novel modalities such as bispecific antibodies developed by companies like Amgen and cell therapies refined at Fred Hutchinson Cancer Research Center. Implementation science and health-policy considerations involve stakeholders such as World Health Organization and payers interacting with regulators including the Food and Drug Administration. Continued advances trace back to collaborations among academic centers like Yale School of Medicine, biotech firms such as Moderna, and philanthropic organizations exemplified by the Bill & Melinda Gates Foundation.